CIK 0001719406 · Non-accelerated filer<br>Smaller reporting company
NRX Pharmaceuticals, Inc.
Sign in to watch- Ticker
- NRXP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 822844431
- Phone
- 484-254-6134
- Business address
- 1201 ORANGE STREET, SUITE 600, WILMINGTON, DE, 19801
- Former names
- Big Rock Partners Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-28 | ABRAMS MICHAEL S Chief Financial Officer | Grant or award · Restricted Stock Unit | +75,000 | 75,000 | ||
| 2026-07-28 | Javitt Jonathan C CEO and Chairman | Grant or award · Restricted Stock Unit | +150,000 | 150,000 | ||
| 2026-01-27 | Casper Joseph Michael Chief Operating Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2025-04-09 | Javitt Jonathan C Chairman and Chief Scientist | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2025-04-09 | McBride Dennis Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2025-04-09 | Hurvitz Chaim Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2025-04-09 | Flynn Patrick John Director | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-02-07 | ABRAMS MICHAEL S Chief Financial Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2024-12-17 | Javitt Jonathan C Chairman and Chief Scientist | Purchase | +40,000 | $1.17 | $47K | 84,634 |
| 2023-08-30 | Gorovitz Aaron Director | Purchase | +35,000 | $0.32 | $11K | 105,000 |
| 2023-08-30 | Hurvitz Chaim Director | Purchase | +70,000 | $0.29 | $20K | 570,000 |
| 2023-08-23 | Javitt Jonathan C Chief Scientist | Purchase | +100,000 | $0.33 | $33K | 446,332 |
| 2023-08-22 | Javitt Jonathan C Chief Scientist | Purchase | +200,000 | $0.32 | $64K | 346,332 |
| 2022-12-16 | Willard Stephen H CHIEF EXECUTIVE OFFICER | Purchase | +50,000 | $1.17 | $59K | 50,000 |
| 2022-12-16 | VAN VOORHEES SETH CHIEF FINANCIAL OFFICER | Purchase | +30,000 | $1.10 | $33K | 46,337 |
| 2022-12-07 | Javitt Jonathan C Director | Sale | −400,000 | $1.00 | $400K | 12,899,997 |
| 2022-11-30 | Javitt Daniel C. 10% owner | Sale | −8,441 | $1.50 | $13K | 9,634,793 |
| 2022-11-29 | Javitt Daniel C. 10% owner | Sale | −13,730 | $1.50 | $21K | 9,643,234 |
| 2022-11-28 | Flynn Patrick John Director | Purchase | +2,500 | $1.25 | $3K | 37,709 |
| 2022-11-28 | Flynn Patrick John Director | Purchase | +2,500 | $1.25 | $3K | 40,209 |
Page 1 of 6 · 108 trades